ClinicalTrials.gg

Program

zeltiprone

Also written as “ONC206”, “ONC206: Dose 1” and “ONC206: Dose 2”.

Its studies are mostly in Central Nervous System Neoplasms · Paraganglioma · Meningioma, led by Jazz Pharmaceuticals.

Furthest: phase 2, since Dec 5, 20253 company-led studies, 3 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals33 open or runningphase 2since Dec 5, 2025Sep 1, 2020Mar 31, 2027phase 1 · NCT04541082

Also a collaborator on its studies: chimerix-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2020First study: phase 1 study in Central Nervous System NeoplasmsFirst studyNCT04541082 · 35 enrolled · United States
  2. Dec 5, 2025Phase 2 study in ParagangliomaPhase 2 reachedNCT07282587 · 90 planned · United States
  3. Apr 10, 2026Phase 2 study in MeningiomaNCT07533942 · 30 planned · United States
  4. Oct 23, 2026Primary completion moved from 2026-07 to 2027-03-31Date moved laterphase 1 · +9 months · NCT04541082

Ahead

  1. Mar 31, 2027Primary completion: phase 1 study in Central Nervous System NeoplasmsNCT04541082
  2. Oct 25, 2028Primary completion: phase 2 study in MeningiomaNCT07533942
  3. Dec 15, 2028Primary completion: phase 2 study in ParagangliomaNCT07282587

TargetBeta

DRD2 →read by rule
“An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, ”NCIt, by rule

Other programs on DRD2

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
rotigotineruleUCBphase 464
lurasidoneruleSumitomo Pharmaphase 452
PramipexoleruleBoehringer Ingelheimphase 444
iloperidoneruleVanda Pharmaceuticalsphase 415
CabergolineruleChangchun GeneScience Pharmaceuticalphase 48
cariprazineruleAbbViephase 341
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07533942Meningioma · United States2RecruitingOct 25, 202830
NCT07282587Paraganglioma · United States2RecruitingDec 15, 202890
NCT04541082Central Nervous System Neoplasms · United States1Active, not recruitingMar 31, 202735

How it is read

Names in the registry

  • “ONC206”, 2 entries
  • “ONC206: Dose 1”, 1 entry
  • “ONC206: Dose 2”, 1 entry
  • “JZP3507”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.